BRANDL TALOS advised shareholders of Allcyte on sale to Exscientia

Press release • Corporate Law & Transactions from Roman Rericha, Stephan Strass, Céline Dobnikar

Exscientia, a leading clinical stage pharmatech company, has entered into a binding agreement to acquire Allcyte, a leader in artificial intelligence (AI) based precision medicine. The transaction is subject to customary regulatory approvals.

The BRANDL TALOS deal team consisted of partner Roman Rericha, attorney Stephan Strass and associate Céline Dobnikar.

Pioneering work by Allcyte has delivered the first clinically validated platform that uses an A.I.-based screening technique to match patients with effective cancer treatments. Therefore, it is possible to select the most promising drug candidates for clinical development to maximize clinical study success rates and patient benefit.

Exscientia, is a U.K. AI-driven pharmatech company that earned accolades as the world’s first company to progress AI-designed small molecules into the clinical setting. The Allcyte transaction comes shortly after Exscientia announced it had received $225 million in Series D venture capital funding from investors that include, among others, SoftBank’s Vision Fund 2, funds managed by BlackRock and Mubadala Investment Co.

By joining Exscientia, Allcyte’s platform will be significantly expanded and extended into early discovery.

 

» We are incredibly excited about the opportunity to immediately apply this technology to a wide range of drug discovery projects at Exscientia. We were very pleased with the work of BRANDL TALOS. Roman, Stephan and team extensively supported us in the exit process, were extremely reliable and incredibly focussed. It was a pleasure working with them and I am looking forward to many further projects. «
Nikolaus Krall, Founder and CEO of Allcyte
» This transaction again shows our expertise in the biotech sector. It is a great success story for the Austrian biotech scene and we are excited to be part of that story,” added Roman Rericha, partner at BRANDL TALOS. «
Roman Rericha

Exscientia was advised by Cooley LLP and Kunz Wallentin. SMP (Frederik Gärtner) acted as advisor to the investors.

The team
Roman Rericha
Partner / Fund Formation, Venture Capital & Start Ups, Corporate Law & Transactions
Roman represents clients in complex cross-border M&A and private equity transactions. Austrian and international venture capital funds regularly turn to him for assisting with investments in Austria. His expert advice also guides start-ups through large-scale financing rounds.

University of Vienna, Faculty of Law (Mag. iur. 2005),
Faculty of Business, Economics and Statistics, (Mag. rer.soc.oec. 2007)
Stephan Strass
Attorney at Law / Venture Capital & Start Ups, Corporate Law & Transactions
Institutional and strategic investors and other companies turn to Stephan for assistance on legal issues including acquisitions, financing rounds, joint ventures, and exit transactions. He has co-authored commentaries on the EU Merger Act and the Investment Fund Act, and is the author of many academic publications.

University of Vienna, Faculty of Law (Mag. iur. 2015)
Harvard Law School, Master of Laws (LL.M. 2019)
Céline Dobnikar
Associate / Venture Capital & Start Ups, Corporate Law & Transactions
Céline is part of our team since 2021.

Karl-Franzens-University Graz (Magistra iuris 2020)